Why is the weak support of innovative treatment for Slovak patients in comparison with EU countries discriminatory? Slovakia has to make a big leap in the systemic setting of drug policy. Why have three large pharmaceutical companies closed their offices in Slovakia and how do global pharmaceutical companies perceive the business environment including political and legislative framework. Do they see the company’s future in Slovakia? We talked with Mateja Cotar, AmCham board member and General Manager at Novartis Oncology, Country President Novartis Slovensko, and Daren Wilson, AmCham Vice President, and General Manager Roche Slovakia. (only in english language)
view more